Let us help you customize your experience.
Tell us a little about yourself so we can share more relevant content and resources.
We are conducting a research study for peanut allergic children. This study evaluates the safety, tolerability, and effectiveness of Dupilumab injections in conjunction with daily peanut oral immunotherapy.
Must be between 6 and 17 years of age, and have a physician documented peanut allergy.